ClinicalTrials.Veeva

Menu

Study Of Indiplon/Placebo With Sertraline In Insomnia Co-Existing With Depression

Neurocrine Biosciences logo

Neurocrine Biosciences

Status and phase

Terminated
Phase 3

Conditions

Insomnia
Depression

Treatments

Drug: Sertraline
Drug: Indiplon

Study type

Interventional

Funder types

Industry

Identifiers

NCT00232167
A5761022

Details and patient eligibility

About

The goal of this study is to determine whether indiplon, when administered with sertraline, improves insomnia symptoms and depressive symptoms in subjects with both insomnia and depression.

Full description

This Pfizer run study stopped due to the co-development program for indiplon being terminated between Pfizer and Neurocrine. The study was terminated on 16 November 2006. There were no safety issues leading to the decision to terminate this study.

Sex

All

Ages

18 to 65 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

  • DSM-IV defined insomnia
  • DSM-IV defined Major Depression

Exclusion criteria

  • Current suicidal ideation or behavior
  • Primary sleep disorder other than insomnia

Trial design

Primary purpose

Treatment

Allocation

Randomized

Interventional model

Parallel Assignment

Masking

Double Blind

Trial contacts and locations

0

Loading...

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems